Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
Immunol Allergy Clin North Am ; 36(3): 547-57, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27401625

RESUMO

Biomarkers have been critical for studies of disease pathogenesis and the development of new therapies in severe asthma. In particular, biomarkers of type 2 inflammation have proven valuable for endotyping and targeting new biological agents. Because of these successes in understanding and marking type 2 inflammation, lack of knowledge regarding non-type 2 inflammatory mechanisms in asthma will soon be the major obstacle to the development of new treatments and management strategies in severe asthma. Biomarkers can play a role in these investigations as well by providing insight into the underlying biology in human studies of patients with severe asthma.


Assuntos
Asma/diagnóstico , Biomarcadores , Antiasmáticos/administração & dosagem , Antiasmáticos/efeitos adversos , Antiasmáticos/uso terapêutico , Asma/etiologia , Asma/terapia , Tomada de Decisão Clínica , Humanos , Prognóstico , Índice de Gravidade de Doença , Resultado do Tratamento
3.
Expert Opin Drug Metab Toxicol ; 10(4): 543-9, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24490943

RESUMO

INTRODUCTION: Topical calcineurin (Cn) inhibitors delivered via ophthalmic drop is emerging as a potential treatment for severe, immune-mediated forms of allergic conjunctivitis, such as vernal keratoconjunctivitis, atopic keratoconjunctivitis and giant papillary conjunctivitis. AREAS COVERED: This article is based on a comprehensive literature search, with information taken from meta-analyses, systematic reviews, treatment guidelines and clinical studies in children and adults. The articles that have been selected evaluate the use of topical Cn inhibitors and their role in the treatment of allergic conjunctivitis. EXPERT OPINION: Ophthalmic topical Cn inhibitors have been shown to be safe for short-term use, with minimal systemic absorption and toxicity. For patients with severe, refractory forms of allergic conjunctivitis, topical Cn inhibitors offer a promising treatment option and an alternative to steroidal therapies. The safety profile and efficacy data for topical cyclosporine are more robust compared to that of tacrolimus and pimecrolimus, although larger trials will be needed for all three agents. With more randomized controlled trials involving larger sample sizes and long-term follow-up to establish both efficacy and safety, ophthalmic Cn inhibitors offer exciting treatment possibilities for the prevention of morbidity associated with refractory allergic conjunctivitis.


Assuntos
Inibidores de Calcineurina , Conjuntivite Alérgica/tratamento farmacológico , Ciclosporina/farmacocinética , Imunossupressores/farmacocinética , Tacrolimo/análogos & derivados , Tacrolimo/farmacocinética , Administração Oftálmica , Ciclosporina/uso terapêutico , Humanos , Imunossupressores/uso terapêutico , Tacrolimo/uso terapêutico , Resultado do Tratamento
4.
Laryngoscope ; 122(12): 2712-22, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23060119

RESUMO

OBJECTIVES/HYPOTHESIS: Postoperative chemoradiation (CRT) has been shown to be more effective than postoperative radiotherapy (RT) alone in high risk head and neck squamous cell carcinoma (HNSCC) patients. Multimodality therapy is associated with more treatment related-toxicity. In this study, we assessed cervical lymph node histological characteristics to detect prognostic and predictive value differences to help guide therapeutic decision making. STUDY DESIGN: Retrospective analysis of Cancer Registry data. METHODS: HNSCC surgical patients who had tumor resection and neck dissection at our institution from 1980 to 2008 were identified (n=1510). Multivariable Cox proportional hazards regression models were developed to identify significant predictors of three outcomes: overall survival (OS), disease-specific survival (DSS), and neck disease recurrence (NDR). Hazard ratios were estimated for the number of cervical nodal metastases and presence of extracapsular spread (ECS) by adjuvant treatment after controlling for significant covariates. RESULTS: Increasing number of positive nodes was significantly associated with poorer outcomes in OS, DSS, and NDR models (p<0.0001, p<0.0001, p=0.0002, respectively). OS and DSS associated with adjuvant treatment (none, RT, or CRT) were modified by number of positive nodes, ECS status, and cancer site. The presence of ECS was associated with reduced OS and DSS (p=0.077, p=0.001 respectively), but not significantly associated with NDR (p=0.179). Nodal positive patients benefited from adjuvant therapy regardless of ECS status. CRT consistently conferred a survival advantage over RT across all nodal categories, although the difference was not statistically significant. CONCLUSIONS: We observed a consistent survival advantage with CRT over RT for patients with positive cervical nodal metastasis, although the difference was not statistically significant.


Assuntos
Carcinoma de Células Escamosas/terapia , Tomada de Decisões , Neoplasias de Cabeça e Pescoço/terapia , Linfonodos/patologia , Cuidados Pós-Operatórios/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/secundário , Quimiorradioterapia/métodos , Feminino , Seguimentos , Neoplasias de Cabeça e Pescoço/diagnóstico , Neoplasias de Cabeça e Pescoço/secundário , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Pescoço , Prognóstico , Estudos Retrospectivos , Carcinoma de Células Escamosas de Cabeça e Pescoço , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA